Sugi Predict

Sugi Predict / Compounds / SCHEMBL8719966

SCHEMBL8719966

SCHEMBL8719966

O=C(CCCC(=O)ON1C(=O)CCC1=O)OCc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.47
▸ L3MBTL1 Q9Y468 3/20 0.47
▸ MAPK1 P28482 3/20 0.47
▸ NOTUM Q6P988 1/20 0.47
▸ EPHX2 P34913 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ CDC25B P30305 1/20 0.41
▸ TDP1 Q9NUW8 2/20 0.41
▸ SLC6A2 P23975 1/20 0.41
▸ SLC6A3 Q01959 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ GLA P06280 1/20 0.40
▸ NPC1 O15118 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ FAAH O00519 1/20 0.40
▸ MGLL Q99685 1/20 0.40
▸ HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16620495 0.97 ALDH1A1 (0.47) ALDH1A1L3MBTL1MAPK1NOTUMEPHX2
SCHEMBL16620483 0.96 EPHX2 (0.46) ALDH1A1L3MBTL1MAPK1NOTUMEPHX2
SCHEMBL8379196 0.96 EPHX2 (0.46) ALDH1A1L3MBTL1MAPK1NOTUMEPHX2
SCHEMBL28612301 0.96 EPHX2 (0.46) ALDH1A1L3MBTL1MAPK1NOTUMEPHX2
SCHEMBL2151608 0.96 EPHX2 (0.46) ALDH1A1L3MBTL1MAPK1NOTUMEPHX2
SCHEMBL24996850 0.96 EPHX2 (0.46) ALDH1A1L3MBTL1MAPK1NOTUMEPHX2
SCHEMBL4271195 0.96 EPHX2 (0.46) ALDH1A1L3MBTL1MAPK1NOTUMEPHX2
SCHEMBL15450611 0.94 NOTUM (0.52) ALDH1A1L3MBTL1MAPK1NOTUMLMNA
Tetrahydrofuran SCHEMBL8376675 0.89 MEN1 (0.44) ALDH1A1L3MBTL1MAPK1NOTUMEPHX2
SCHEMBL2560120 0.88 NOTUM (0.44) ALDH1A1L3MBTL1MAPK1NOTUMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4561585-A1 IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION, AND PREVENTION OF ECTOPIC CALCIFICATION Sanifit Therapeutics S.A. (ES) 2025-06-04 — — EP disclosed
CN-119855595-A IP4-4,6 substituted derivative compounds for treating ectopic calcification, inhibiting progression and preventing ectopic calcification 萨尼菲特治疗有限公司 2025-04-18 — — CN disclosed
US-20240109924-A1 IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS VIFOR (INTERNATIONAL) LTD. (CH) 2024-04-04 — — US disclosed
WO-2024023359-A1 IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS FOR USE IN THE TREATMENT, INHIBITION OF PROGRESSION, AND PREVENTION OF ECTOPIC CALCIFICATION SANIFIT THERAPEUTICS, S.A. (ES) 2024-02-01 — — WO disclosed
EP-4284809-A1 IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS Sanifit Therapeutics S.A. (ES) 2023-12-06 — — EP disclosed
WO-2022162206-A1 IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS SANIFIT THERAPEUTICS, S.A. (ES) 2022-08-04 — — WO disclosed
EP-4036097-A1 IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS Sanifit Therapeutics S.A. (ES) 2022-08-03 — — EP disclosed
EP-3052134-B1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME (US) 2021-05-05 — — EP disclosed
US-20200276261-A1 A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2020-09-03 — — US disclosed
US-20180110863-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2018-04-26 — — US disclosed
US-9889205-B2 Glucose-responsive insulin conjugates MERCK SHARP & DOHME CORP. (US) 2018-02-13 — — US disclosed
US-9884125-B2 Glucose-responsive insulin conjugates MERCK SHARP & DOHME CORP. (US) 2018-02-06 — — US disclosed
US-20160303244-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2016-10-20 — — US disclosed
WO-2016164288-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2016-10-13 — — WO disclosed
US-20160251407-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2016-09-01 — — US disclosed
US-9427475-B2 Glucose-responsive insulin conjugates MERCK SHARP & DOHME CORP. (US) 2016-08-30 — — US disclosed
EP-3052134-A2 GLUCOSE-RESPONSIVE INSULIN CONJUGATES Merck Sharp & Dohme Corp. (US) 2016-08-10 — — EP disclosed
US-20150105317-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME LLC 2015-04-16 — — US disclosed
WO-2015051052-A2 GLUCOSE-RESPONSIVE INSULIN CONJUGATES MERCK SHARP & DOHME CORP. (US) 2015-04-09 — — WO disclosed
WO-1998008854-A2 SUGAR DERIVATIVES AS SIALYL LEWIS X MIMETICS NOVARTIS AG (CH) 1998-03-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180110863-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES GPR119, INSR, IRS1 ALDH1A1 3422/4885L3MBTL1 1778/4885MAPK1 1186/4885
US-20150105317-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES GPR119, INSR, IRS1 ALDH1A1 3285/4885L3MBTL1 1526/4885MAPK1 1090/4885
US-20160251407-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES GPR119, INSR, IRS1 ALDH1A1 3459/4885L3MBTL1 1356/4885MAPK1 1013/4885
US-20240109924-A1 IP4-4,6 SUBSTITUTED DERIVATIVE COMPOUNDS IPO4, TPX2, IPO9 ALDH1A1 4700/4885L3MBTL1 3016/4885MAPK1 4308/4885
US-20200276261-A1 A CONJUGATE OF A TUBULYSIN ANALOG WITH BRANCHED LINKERS TEKT1, TEK, BTN3A1 ALDH1A1 4604/4885L3MBTL1 1087/4885MAPK1 2442/4885
US-20160303244-A1 GLUCOSE-RESPONSIVE INSULIN CONJUGATES GPR119, INSR, IRS1 ALDH1A1 3285/4885L3MBTL1 1526/4885MAPK1 1090/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.